Next-Gen BCL2 Inhibitor Approved for Aggressive Lymphoma

(MedPage Today) — The FDA has granted accelerated approval to sonrotoclax (Beqalzi) as the first BCL2 inhibitor for relapsed or refractory mantle cell lymphoma (MCL), a rare and often aggressive subtype of non-Hodgkin’s lymphoma. A new generation…